The stock of Compass Therapeutics Inc (CMPX) has gone down by -8.95% for the week, with a 8.81% rise in the past month and a 81.70% rise in the past quarter. The volatility ratio for the week is 8.48%, and the volatility levels for the past 30 days are 8.75% for CMPX. The simple moving average for the last 20 days is -1.03% for CMPX stock, with a simple moving average of 16.15% for the last 200 days.
Is It Worth Investing in Compass Therapeutics Inc (NASDAQ: CMPX) Right Now?
The 36-month beta value for CMPX is at 0.71. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 4 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CMPX is 85.81M, and currently, shorts hold a 2.68% of that float. The average trading volume for CMPX on October 09, 2024 was 418.00K shares.
CMPX) stock’s latest price update
The stock price of Compass Therapeutics Inc (NASDAQ: CMPX) has plunged by -10.82 when compared to previous closing price of 1.94, but the company has seen a -8.95% decline in its stock price over the last five trading sessions. globenewswire.com reported 2024-10-04 that BOSTON, Oct. 04, 2024 (GLOBE NEWSWIRE) — Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the acceptance of an abstract for poster presentation at the upcoming 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held from November 8–10, 2024 at the George R. Brown Convention Center in Houston, TX.
Analysts’ Opinion of CMPX
Many brokerage firms have already submitted their reports for CMPX stocks, with Ladenburg Thalmann repeating the rating for CMPX by listing it as a “Buy.” The predicted price for CMPX in the upcoming period, according to Ladenburg Thalmann is $5 based on the research report published on September 16, 2024 of the current year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see CMPX reach a price target of $8. The rating they have provided for CMPX stocks is “Buy” according to the report published on January 31st, 2023.
Stifel gave a rating of “Buy” to CMPX, setting the target price at $9 in the report published on January 27th of the previous year.
CMPX Trading at 20.72% from the 50-Day Moving Average
After a stumble in the market that brought CMPX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -26.07% of loss for the given period.
Volatility was left at 8.75%, however, over the last 30 days, the volatility rate increased by 8.48%, as shares surge +9.49% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +58.72% upper at present.
During the last 5 trading sessions, CMPX fell by -8.95%, which changed the moving average for the period of 200-days by +8.81% in comparison to the 20-day moving average, which settled at $1.7480. In addition, Compass Therapeutics Inc saw 10.90% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for CMPX
Current profitability levels for the company are sitting at:
- -18.79 for the present operating margin
- 0.34 for the gross margin
The net margin for Compass Therapeutics Inc stands at -15.98. The total capital return value is set at -0.34. Equity return is now at value -30.05, with -28.22 for asset returns.
Based on Compass Therapeutics Inc (CMPX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -29.92. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -28.51.
Currently, EBITDA for the company is -48.47 million with net debt to EBITDA at 0.43. When we switch over and look at the enterprise to sales, we see a ratio of 75.87. The liquidity ratio also appears to be rather interesting for investors as it stands at 16.15.
Conclusion
In conclusion, Compass Therapeutics Inc (CMPX) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
